Comparison of GnRH agonists and antagonists the outcome IVF/ICSI in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402041760N30

Enrollment

120

Registered

2014-03-03

Start date

2013-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention Groups: Agonist group GNRH, starting the cycle period of 2-3 days, 14-21 days, take one tablet daily for 21 days and the LD cycle Busereline 500mg Super artifact constru

Treatment - Drugs

Intervention Groups: Agonist group GNRH, starting the cycle period of 2-3 days, 14-21 days, take one tablet daily for 21 days and the LD cycle Busereline 500mg Super artifact construction company (

Control Groups: Aldo Group ovulation period of 2-3 days with Gonal F starts in people younger than 30 years with 2 injections (150 units) and in women older than 30 years with 3 injections (225 un

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: PCOs; having two of the three diagnostic criteria Rotterdam 2003(Irregular menstruation oligomenorrhea, amenorrhea and irregular bleeding); hyperandrogenism(Hirsutism, severe acne, hair loss); obesity; polycystic ovaries on ultrasound to rule out specific diseases such as disorders of the hypothalamus, pituitary or other causes hyperandrogenism ; age = 35 years; FSH <12 mlu / ml on days 2-3 of the cycle Exclusion criteria: history of more than two abortions; in laparoscopic uterine anomaly, hysteroscopy & hysterosonography; ovarian cysts.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy. Timepoint: 7-6 weeks to see the gestational sac. Method of measurement: Ultrasound.	—

Secondary

Measure	Time frame
Duration of ovarian stimulation. Timepoint: Duration of drug use. Method of measurement: Clinical.;Number of drugs. Timepoint: Duration of treatment. Method of measurement: clinical.;The cost. Timepoint: Time to confirm pregnancy. Method of measurement: Amount spent.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarmar Firoozpour Bandepei

Fatemehzahra Fertility & reproductive Health Reseach Center

farazmarmar@gmail.com+98 11 1227 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026